

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications (Non-Prescription Items) PM	Date of Authorisation
0339/0046	Radiol Chemicals Limited (/a Fisons Consumer Health)	Secoderm Salve	Resin (Colophony) BP 26% w/w Turpentine Oil BP 6% w/w Melaleuca Oil BPC 1949 BPC 5.6% w/w Terebene 5.25% w/w Phenol BP 2.4% w/w	Except POM cases: Indicated in the treatment of boils, minor skin infections. GSL	19th October 1992
0339/0047	Radiol Chemicals Limited (/a Fisons Consumer Health, Dublin)	Caldesene Medicated Powder	Calcium Undecylenate 10.00% w/w	Except POM cases: For the prevention and treatment of local rashes of buttocks due to friction and irritation including prickly heat and chafing. For the prophylaxis of nappy rash. GSL	19th October 1992
0339/0048	Radiol Chemicals Limited (/a Fisons Consumer Health, Dublin)	F3 Squeeze Powder	Calcium Undecylenate 10.00% w/w	Except POM cases: As an adjunct to the treatment of jock-itch fungus (tinea cruris—dubois itch). Absorbs perspiration. GSL	19th October 1992
0339/0049	Radiol Chemicals Limited (/a Fisons Consumer Health)	Desenex Powder	Zinc Undecenoate Ph Eur 20.0% w/w Undecenoic Acid Ph Eur 2.0% w/w	Except POM cases: For the prophylaxis and treatment of mycotic superficial dermatophytoses of feet, axillae and groin. GSL	19th October 1992
0339/0050	Radiol Chemicals Limited (/a Fisons Consumer Health)	Desenex Ointment	Zinc Undecenoate Ph Eur 20% w/w Undecenoic Acid Ph Eur 5% w/w	Except POM cases: The treatment of mycotic superficial dermatophytoses and the relief of itching and scaling produced by these fungal infections. GSL	19th October 1992
0426/0066	Allergan Limited	Oxysept 1-Step Neutralising Tablet	Catalase HSE 5200 u	Recommended Contact Lens Care Use: For use in the Oxysept 1-Step cleaning and disinfection system to neutralise the hydrogen peroxide in Oxysept 1-Step Disinfecting Solution.	28th October 1992
0426/0070	Allergan Limited	Exocin TM 0.3% w/v	Olozoxin HSE 0.3% w/v	POM	26th October 1992
0504/0016	Wallace, Cameron and Company Limited	Ultra Steriflow (Pods)	Sodium Dihydrogen Phosphate Dihydrate BP 0.52% w/v Disodium Hydrogen Phosphate Dodecahydrate BP 1.19% w/v Sodium Chloride BP 0.48% w/v	Except POM cases: Buffered isotonic solution for washing injurious chemicals, foreign bodies from the eye. GSL	23rd October 1992
0530/0389	Norton Healthcare Limited (/a H. N. Norton)	Cephalexin 250 mg Tablets BP	Cephalexin BP 250 mg	POM	22nd December 1992
0530/0390	Norton Healthcare Limited (/a H. N. Norton)	Cephalexin 500 mg Tablets BP	Cephalexin BP 500 mg	POM	22nd December 1992
1817/0017	Mallinckrodt Medical (UK) Limited	Optiray-300 (Injection 636 mg/ml)	Ioversol HSE 636 mg	POM	30th October 1992
1817/0018	Mallinckrodt Medical (UK) Limited	Optiray-350 (Injection 741 mg/ml)	Ioversol HSE 741 mg	POM	30th October 1992
3157/0008	Combe International Limited	Lanacort Creme	Hydrocortisone Acetate BP 1.000% w/w	Except POM cases: Irritant Dermatitis, Contact Allergic Dermatitis and Insect Bite reactions. PM	1st October 1992
3157/0011	Combe International Limited	Lanacort Ointment	Hydrocortisone Acetate BP 1.000% w/w	Except POM cases: Irritant Dermatitis, Contact Allergic Dermatitis and Insect Bite reactions. PM	1st October 1992
3400/0021	Serono Laboratories (UK) Limited	Profasi 10,000 iu	Chorionic Gonadotrophin HSE 10 ku	POM	2nd October 1992
4416/0216	Lagap Pharmaceuticals Limited	Ferrous Sulphate Tablets 200 mg	Ferrous Sulphate BP 200 mg	Except POM cases: Iron-deficiency anaemia. PM	12th January 1993
4425/0127	Marion Merrell Dow Limited	Nicabate Transdermal Patch 7 mg/Day	Nicotine HSE 36.0 mg	Except POM cases: Nicabate is indicated for the relief of nicotine withdrawal symptoms associated with smoking cessation. If possible, Nicabate should be used with concurrent behavioural support therapy. PM	30th October 1992
4425/0128	Marion Merrell Dow Limited	Nicabate Transdermal Patch 14 mg/Day	Nicotine HSE 78.0 mg	Except POM cases: Nicabate is indicated for the relief of nicotine withdrawal symptoms associated with smoking cessation. If possible, Nicabate should be used with concurrent behavioural support therapy. PM	30th October 1992
4425/0129	Marion Merrell Dow Limited	Nicabate Transdermal Patch 21 mg/Day	Nicotine HSE 114.0 mg	Except POM cases: Nicabate is indicated for the relief of nicotine	30th October 1992